Using blood tests for circulating tumor DNA to guide treatment in gastric cancer
Official title: A Prospective Phase II Study of Dynamic Circulating Tumor DNA to Predict and Guide Systemic Treatment in Patients With Gastric Cancer
Run by Fudan University · NCT07517107 · Data updated 2026-11-12
This will test whether regular blood tests that measure circulating tumor DNA can help guide systemic treatment for adults with gastric or gastroesophageal junction adenocarcinoma.
Quick facts
| Phase | Phase 2 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 600 (estimated) |
| Sponsor | Fudan University Academic / other |
| Drugs / interventions | chemotherapy, immunotherapy |
| Locations | 1 site (Shanghai) |
| Status | Recruiting |
| Started | January 1, 2026 |
| Main results expected | October 1, 2028 |
| Study ends | October 1, 2029 |
| Registry record updated | April 8, 2026 |
| Trial ID | NCT07517107 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults (≥18 years) with histologically confirmed gastric or gastroesophageal junction adenocarcinoma, ECOG 0-2, adequate organ function, and planned for neoadjuvant, adjuvant, or systemic therapy who can provide informed consent and serial blood samples are ideal candidates.
✕Probably not a fit
Patients whose tumors shed little or no ctDNA, those with severe organ dysfunction or very limited life expectancy, or those unable to attend the single-site visits are unlikely to benefit from this approach.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is a prospective, open-label, single-center phase II study conducted at Fudan University Shanghai Cancer Center. Patients are enrolled into three cohorts based on treatment stage: neoadjuvant/conversion therapy, adjuvant therapy after curative surgery, or advanced/metastatic disease. Participants receive standard systemic therapy while undergoing serial blood sampling for circulating tumor DNA (ctDNA) analysis, and ctDNA trends may be used to inform treatment decisions alongside imaging and clinical assessment. Key endpoints include the relationship between ctDNA dynamics and treatment response, detection of minimal residual disease, and potential impact on treatment selection and outcomes.
Why it matters
Potential benefit: If successful, this approach could detect response or recurrence earlier and help personalize systemic therapy to improve outcomes and avoid ineffective treatments.
How similar studies have gone: Prior work in other cancers and early reports in gastric cancer show ctDNA can detect minimal residual disease and predict relapse, but using ctDNA to directly guide treatment decisions remains largely experimental.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: \- Age ≥18 years. Histologically or cytologically confirmed gastric or gastroesophageal junction adenocarcinoma. Eastern Cooperative Oncology Group (ECOG) performance status of 0-2. Adequate organ function within 7 days prior to enrollment, including: Absolute neutrophil count ≥1.5 × 10⁹/L Platelet count ≥80 × 10⁹/L Hemoglobin ≥80 g/L Total bilirubin ≤1.5 × upper limit of normal (ULN) AST and ALT ≤2.5 × ULN (≤5 × ULN in case of liver metastases) Serum creatinine ≤1.5 × ULN or creatinine clearance ≥60 mL/min Serum albumin ≥30 g/L Estimated life expectancy ≥3 months. Willingness to provide blood samples for circulating tumor DNA (ctDNA) analysis. Signed written informed consent prior to any study-related procedures. Cohort-Specific Inclusion Criteria: Neoadjuvant/Conversion Cohort: 8\. Planned to receive neoadjuvant or conversion systemic therapy followed by potential surgery. 9\. Locally advanced (T3-T4a and/or N+, M0) or oligometastatic disease (≤1 metastatic organ and ≤5 lesions) considered potentially resectable after systemic therapy. 10\. No prior systemic therapy for gastric cancer. Adjuvant Cohort: 11\. Completion of curative-intent surgery for gastric cancer. 12. Pathological stage II-III disease without distant metastasis. 13. Planned to receive standard adjuvant chemotherapy (e.g., XELOX or SOX). Advanced Disease Cohort: 14\. Unresectable or metastatic disease not amenable to curative surgery. 15. Planned to receive systemic therapy, including chemotherapy with or without immunotherapy, as first-line or later-line treatment. 16\. At least one measurable lesion according to RECIST v1.1. Exclusion Criteria: \- History of another malignancy within 5 years, except for adequately treated carcinoma in situ of the cervix or non-melanoma skin cancer. Uncontrolled central nervous system metastases or primary brain tumors. Severe or uncontrolled comorbidities, including but not limited to: Unstable cardiovascular disease (e.g., recent myocardial infarction, unstable angina, congestive heart failure) Severe infection Active disseminated intravascular coagulation Significant bleeding tendency Significant organ dysfunction that, in the investigator's judgment, would compromise patient safety. Symptomatic pleural effusion or ascites requiring intervention. Any condition that, in the opinion of the investigator, would make the patient unsuitable for participation in the study.
Where it's running
-
Fudan University Shanghai Cancer Center
Shanghai, China Recruiting
Study contacts
- Principal investigator: Weijian Guo — Fudan University
- Study coordinator: Weijian Guo
- Email: guoweijian1@hotmail.com
- Phone: 02164175590
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
CG-7321: a first-in-human test in advanced solid tumors
We’re testing CG-7321 alone and with fulvestrant to see if it’s safe and tolerable in adults with advanced solid tumors.
-
Neoadjuvant trastuzumab, durvalumab, and FLOT for HER2-positive gastric or GEJ cancer
This study tests a pre-surgery treatment combining trastuzumab, durvalumab, and FLOT for patients with HER2-positive locally advanced gastric or gastroesophageal junction cancer to see how many achieve complete tumor disappearance.
-
Integrated genomic and clinical database for cancer biomarker discovery
Researchers are building a combined genomic and clinical database at Samsung Medical Center to test biomarkers for cancer diagnosis, treatment choice, and predicting how well treatments work.
-
Adding 2141-V11 to standard therapy for advanced esophageal, gastric, or gastroesophageal junction cancer
This study tests whether adding the drug 2141-V11 to standard anti-PD-1 therapy (with or without 5-FU) is safe for adults with advanced or metastatic esophageal, gastric, or gastroesophageal junction adenocarcinoma.
-
Guaraná Supplement for Cancer-Related Fatigue in People Undergoing Treatment
This study tests whether taking guaraná capsules helps reduce cancer-related fatigue and improve quality of life in adults with breast, lung, colorectal, or gastric cancer who are actively receiving treatment.
-
ABBV-253 in adults with advanced solid tumors
This study tests ABBV-253 to see if it is safe, how it affects the cancer, and how the drug moves in the body for adults with advanced solid tumors.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.